Amylyx Pharmaceuticals AMLX Stock
Amylyx Pharmaceuticals Price Chart
Amylyx Pharmaceuticals AMLX Financial and Trading Overview
| Amylyx Pharmaceuticals stock price | 13.2 USD |
| Previous Close | 14.35 USD |
| Open | 14.09 USD |
| Bid | 10.03 USD x 200 |
| Ask | 17.83 USD x 200 |
| Day's Range | 13.9 - 14.24 USD |
| 52 Week Range | 4.76 - 18.61 USD |
| Volume | 671.2K USD |
| Avg. Volume | 1.1M USD |
| Market Cap | 1.56B USD |
| Beta (5Y Monthly) | -0.103 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.48 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.4 USD |
AMLX Valuation Measures
| Enterprise Value | 1.32B USD |
| Trailing P/E | N/A |
| Forward P/E | -11.113744 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 5.719512 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -8.321 |
Trading Information
Amylyx Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | -0.103 |
| 52-Week Change | 181.37% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 18.61 USD |
| 52 Week Low | 4.76 USD |
| 50-Day Moving Average | 15.24 USD |
| 200-Day Moving Average | 13.68 USD |
AMLX Share Statistics
| Avg. Volume (3 month) | 1.1M USD |
| Avg. Daily Volume (10-Days) | 935.93K USD |
| Shares Outstanding | 111.19M |
| Float | 83.53M |
| Short Ratio | 12.95 |
| % Held by Insiders | 7.91% |
| % Held by Institutions | 105.09% |
| Shares Short | 14.51M |
| Short % of Float | 16.89% |
| Short % of Shares Outstanding | 13.05% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -38.78% |
| Return on Equity (ttm) | -63.26% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -95895000 USD |
| EBITDA | -158800000 USD |
| Net Income Avi to Common (ttm) | -150112000 USD |
| Diluted EPS (ttm) | -1.48 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 279.77M USD |
| Total Cash Per Share (mrq) | 2.52 USD |
| Total Debt (mrq) | 5.63M USD |
| Total Debt/Equity (mrq) | 2.06 USD |
| Current Ratio (mrq) | 17.852 |
| Book Value Per Share (mrq) | 2.46 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -120401000 USD |
| Levered Free Cash Flow (ttm) | -71515872 USD |
Profile of Amylyx Pharmaceuticals
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 55 Cambridge Parkway |
| ZIP | 02142 |
| Phone | 617 682 0917 |
| Website | https://amylyx.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 136 |
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Q&A For Amylyx Pharmaceuticals Stock
What is a current AMLX stock price?
Amylyx Pharmaceuticals AMLX stock price today per share is 13.2 USD.
How to purchase Amylyx Pharmaceuticals stock?
You can buy AMLX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Amylyx Pharmaceuticals?
The stock symbol or ticker of Amylyx Pharmaceuticals is AMLX.
Which industry does the Amylyx Pharmaceuticals company belong to?
The Amylyx Pharmaceuticals industry is Drug Manufacturers - Specialty & Generic.
How many shares does Amylyx Pharmaceuticals have in circulation?
The max supply of Amylyx Pharmaceuticals shares is 111.19M.
What is Amylyx Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Amylyx Pharmaceuticals PE Ratio is now.
What was Amylyx Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Amylyx Pharmaceuticals EPS is -1.48 USD over the trailing 12 months.
Which sector does the Amylyx Pharmaceuticals company belong to?
The Amylyx Pharmaceuticals sector is Healthcare.
Amylyx Pharmaceuticals AMLX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech US 700 Small Cap Index NQUS700SC | 2992.49 USD — |
-1.38
|
— — | 2986.86 USD — | 3018.97 USD — | — - | — — |
| US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG | 4054.02 USD — |
-0.25
|
— — | 4019.75 USD — | 4077 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}